Timothy Donovan Email and Phone Number

* Responsible for growing 5 product categories generating 20 million in sales * Develop new products managing from concept, to design, sample production, testing, forecast, cost, mass production and promotion* Responsible for achievement of growth objectives including market share, revenue, profit and return on investment for all the channels/categories of business * Responsible for managing and implementing marketing activities through research, strategic planning and implementation.

Develop strategic and tactical business plans which effectively lead to the development of new businesses or improve market share. Define and implement go to market strategy and value propositions based on segmentation, targeting and positioning

Supported company efforts in identifying & qualifying reliable domestic suppliers for all current & proposed BBC product offerings. Responsible for negotiating pricing to support specific RFQ goals.• Developed and qualified new sources/vendors by obtaining best price/delivery • Secured exclusivity agreements with vendors providing Bob Barker Company exclusive distribution of specific products in the corrections market• Lead specific strategic projects that would expand Bob Barkers product line into parallel markets • Negotiated Co-op dollars from new vendors to support marketing efforts • Worked effectively with all departments (purchasing, bids, marketing, sales, finance and customer service) to achieve department/company goals

Responsible for profitable access, coverage and reimbursement in regional commercial, Part D and Medicaid payers for UCB’s promoted products (Cimzia, Keppra XR and Vimpat) . Managed 5 Regional Account Managers covering 12 state Medicaid Agencies and 52 Managed Care Organizations● Lead team to consistently exceed corporate/segment sales and access goals ● Lead National Account Team covering Caremark, UHC, Coventry, Aetna and Cigna for 6 months until National Director was hired ● Participated in the formulation of brand strategic plans. Integrated corporate marketing strategies into segment plan

Ensured optimal access, coverage, and reimbursement in the government payers including Medicare, Medicaid and the VA/DOD for UCB’s entire product portfolio (Cimzia, Keppra, Keppra XR, Neupro and Metadate CD) ● Lead team of 8 account executives to consistently exceed national goals including State Preferred Drug Lists, Supplemental Rebates and Local Medical Review Policies● Established organization design, staffed and initiated developmental programming for 8 account executives covering US● Determined staffing, budget needs and operating procedures for newly formed Government Reimbursement Department ● Developed and lead execution of Medicaid and VA/DoD contracting strategy for Cimzia, Neupro, Keppra XR and Vimpat● Developed and lead execution of Medicare Part B strategy for Cimzia● Developed Keppra IR Medicaid protection strategy against generic erosion. Maintained 83% of Keppra IR share 6 months post generic entry ● Assumed Vice President of Managed Markets responsibilities reporting to President of US operation for 6 months until open position was filled ● Provided strategic direction to President US Operations related to FDA Amendment Act and impact to UCB commercializing new drugs ● 2006 vs. 2007 performance:o Won all state PDL contracts allowing Keppra parity or better PDL positioning in all 52 states while saving $1.3M in rebate vs. 2006 o Dollar growth in the Medicaid segment increased by 17% in 2007 vs. 2006 ($135M to $164M)o Implemented the entire Keppa franchise on all 21 VISNs o VA Keppra dollar growth in 2007 vs. 2006 increased 54% ($12M incremental dollars ) o Keppra VA market share grew from 8% to 12% 2007 vs. 2006 o Implemented the entire Keppa franchise on the top 18 Military Treatment Center formularies o DoD Keppra dollar growth in 2007 vs. 2006 increased 29% ($3.6M incremental dollars

Responsible for favorable access, coverage and reimbursement in the commercial and public payers for Amgen’s entire product portfolio (Epo, Aranesp, Neupogen, Neulasta and Enbrel● Effectively managed 8 Corporate Account Managers covering 14 state Medicaid Agencies and 52 Managed Care Organizations ● Lead team to consistently exceed corporate/segment goals including State Preferred Drug Lists, Supplemental Rebates and Local Medical Review Policies● Successfully lead cross-functional business initiatives. Participated in the formulation of brand strategic plans ● Integrated corporate marketing strategies into segment plan

Managed 5 national account dialysis chains (FMC, RCG, DaVita, Gambro, DCI) representing over $130M in annual sales.● Increased total Calcijex sales by 52% from 8/99 to 8/00. Increased new product sales (Zemplar) by 167% from 8/99 to 8/00.● Negotiated long term contracts with each national account.● Exceeded Zemplar transition goals in the top 4 national accounts, which represent 61% of overall business.

Sold 3 pharmaceutical product lines to all nephrologists in Pennsylvania and West Virginia● Effectively promoted 3 product lines to all nephrologists in Pennsylvania and West Virginia.● Consistently produce double-digit market share growth (Calcijex and Abbokinase) from 1995 to 1999.● Awarded Rookie of the Year in 1995.● Ranked #2 in US for Abbokinase sales in 1996